TR201001117A1 - Dimebolin ve memantin kombinasyonları - Google Patents

Dimebolin ve memantin kombinasyonları

Info

Publication number
TR201001117A1
TR201001117A1 TR2010/01117A TR201001117A TR201001117A1 TR 201001117 A1 TR201001117 A1 TR 201001117A1 TR 2010/01117 A TR2010/01117 A TR 2010/01117A TR 201001117 A TR201001117 A TR 201001117A TR 201001117 A1 TR201001117 A1 TR 201001117A1
Authority
TR
Turkey
Prior art keywords
memantine
dimebolin
combinations
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
TR2010/01117A
Other languages
English (en)
Inventor
Toksöz Ahmet
Ümi̇t Çi̇fter Musa
Türkyilmaz Ali̇
Original Assignee
Sanovel İlaç San.Ve Ti̇c.A.Ş.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel İlaç San.Ve Ti̇c.A.Ş. filed Critical Sanovel İlaç San.Ve Ti̇c.A.Ş.
Priority to TR2010/01117A priority Critical patent/TR201001117A1/tr
Priority to EP11154578A priority patent/EP2363120A1/en
Publication of TR201001117A1 publication Critical patent/TR201001117A1/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Buluş farmasötik kombinasyon olup özelliği, dimebolin veya dimebolinin farmasötik olarak kabul edilebilir bir tuzu ile memantın veya memantın farmasötik olarak kabul edilebilir bir tuzunu içermesi ile karakterize edilmektedir.
TR2010/01117A 2010-02-15 2010-02-15 Dimebolin ve memantin kombinasyonları TR201001117A1 (tr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
TR2010/01117A TR201001117A1 (tr) 2010-02-15 2010-02-15 Dimebolin ve memantin kombinasyonları
EP11154578A EP2363120A1 (en) 2010-02-15 2011-02-15 Combinations of dimebolin and memantine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2010/01117A TR201001117A1 (tr) 2010-02-15 2010-02-15 Dimebolin ve memantin kombinasyonları

Publications (1)

Publication Number Publication Date
TR201001117A1 true TR201001117A1 (tr) 2011-09-21

Family

ID=42272662

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2010/01117A TR201001117A1 (tr) 2010-02-15 2010-02-15 Dimebolin ve memantin kombinasyonları

Country Status (2)

Country Link
EP (1) EP2363120A1 (tr)
TR (1) TR201001117A1 (tr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008051599A2 (en) * 2006-10-27 2008-05-02 Medivation Neurology, Inc. Combination therapies for treating alzheimer's disease using i. a. dimebon and dolepezil
WO2008112238A1 (en) * 2007-03-12 2008-09-18 Grey Fox Llc 2, 8-dimethyl-5- [2- (6-methylpyridin-3-yl) -ethyl] -2,3,4, 5-tetrahydro- ih- pyrido [4, 3 -b] indole dihydrochloride (dimebon) for the treatment of chronic pain

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2106864C1 (ru) 1995-10-23 1998-03-20 Николай Серафимович Зефиров Средство для лечения болезни альцгеймера
GEP20094759B (en) 2002-10-24 2009-08-25 Merz Pharma Gmbh & Co Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
RU2283108C2 (ru) 2003-12-08 2006-09-10 Сергей Олегович Бачурин ГЕРОПРОТЕКТОР НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
ES2362926T3 (es) 2005-09-22 2011-07-15 EISAI R&D MANAGEMENT CO., LTD. Nueva combinación de fármacos como un antidepresivo.
EP1886670A1 (en) 2006-07-05 2008-02-13 Teva Pharmaceutical Industries Ltd Pharmaceutical compositions of memantine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008051599A2 (en) * 2006-10-27 2008-05-02 Medivation Neurology, Inc. Combination therapies for treating alzheimer's disease using i. a. dimebon and dolepezil
WO2008112238A1 (en) * 2007-03-12 2008-09-18 Grey Fox Llc 2, 8-dimethyl-5- [2- (6-methylpyridin-3-yl) -ethyl] -2,3,4, 5-tetrahydro- ih- pyrido [4, 3 -b] indole dihydrochloride (dimebon) for the treatment of chronic pain

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CLINICAL TRIALS: "Safety and Tolerability of Dimebon in Patients on Memantine, and Memantine Plus Donepezil", 14 April 2009 (2009-04-14), XP002590358, Retrieved from the Internet <URL:http://clinicaltrials.gov/ct2/show/NCT00829816> [retrieved on 20100701] *

Also Published As

Publication number Publication date
EP2363120A1 (en) 2011-09-07

Similar Documents

Publication Publication Date Title
EA201200550A1 (ru) Фармацевтические композиции, включающие bi-1356 и метформин
CL2015000345A1 (es) Uso de una combinación para el melanoma que comprende la administración de cobimetinib y vemurafenib.
CL2013003577A1 (es) Uso de una composicion farmaceutica que comprende panobinostat y ruxolitinib en la prevencion y/o tratamiento de neoplasias mieloproliferativas.
CL2009001099A1 (es) Uso de una muteina de interleuquina-2 humana para el tratamiento y/o prevencion de una enfermedad autoinmune.
AU352424S (en) Hand tightened hydraulic fitting
CY1121999T1 (el) Φαρμακοτεχνικες μορφες συνδυασμου δαρουναβιρης
EA201390074A1 (ru) 5-хлор-4-гидрокси-1-метил-2-оксо-n-фенил-1,2-дигидрохинолин-3-карбоксамид, его соли и применения
AU339376S (en) Sterilizing case
TR201102067A1 (tr) Valsartan ve amlodipin kombinasyonları.
ES2415029A8 (es) Composición farmacéutica y uso de un anticuerpo para preparar un medicamento destinado a inhibir la producción o amplificar la eliminación de la proteína P24.
AU331636S (en) Sweeper foot
ECSP10010661A (es) Dronedarona para la prevención de la cardioversión
BR112012002311A2 (pt) composto, composição farmacêutica, e, uso do composto.
CL2011003248A1 (es) Composicion farmaceutica que comprende crf y un inhibidor de angiogenesis; util para la prevencion y el tratamiento del cancer.
TR200903014A1 (tr) Oral yolla dağılan dimebolin bileşimleri.
TR201001117A1 (tr) Dimebolin ve memantin kombinasyonları
AU345245S (en) Muffler
AU334516S (en) Bowl
TR201007926A1 (tr) Prasugrel tablet formülasyonları.
TR201101809A1 (tr) Vildagliptin ve glimepirid kombinasyonları.
TR201107563A1 (tr) Vildagliptin ve gliklazid kombinasyon kompozisyonu.
TR201005419A2 (tr) Valsartan içeren farmasötik bileşim.
TH121711B (th) รูปแบบขนาดยาเภสัชวิทยาซึ่งที่ควรใช้คือยาเม็ดกลมแบนที่ประกอบรวมด้วยส่วนนูนบนด้านหน้าและ/หรือ ด้านหลังของมัน
AU343097S (en) Cam lock
AU334436S (en) Bed base end